Nantes

• Treatment protocol for osteosarcomas in children, adolescents and adults including a randomized trial and biological studies Ended recruitment
  2024-514756-32-00 5 2007-03-19 High grade osteosarcoma
• Avacopan added to standard-of-care therapy in ANCA-associated vasculitis with severe kidney involvement Halted
  2024-519620-24-01 5 2026-06-01 ANCA-associated vasculitis
• Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis Halted
  2024-516687-28-00 5 2025-06-06 Patients with GPA and inadequate response to standard of care therapy
• A trial to understand if AZD0486 is safe and helps in people with Relapsed or Refractory B-cell acute lymphoblastic leukemia (B-ALL) Halted
  2023-505840-20-00 9 2024-08-16 B-Cell Acute Lymphoblastic Leukaemia
• Phase 2 Study of CAL02 plus Standard of Care in Severe Community-Acquired Bacterial Pneumonia (SCABP) Halted
  2022-502049-91-00 4 2023-09-26 SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP)
• Spartalizumab and low-dose PAzopanib in Refractory or Relapsed solid TumOrs of pediatric and adults SPARTO Halted
  2024-513535-24-00 9 2022-05-02 Refractory or Recurrent Solid Tumor
• Phase 1 study of a Propranolol (HEMANGIOL®) and oral metronomic Vinorelbine (NAVELBINE®) combination on children and teenagers With Refracto … Halted
  2024-517185-42-00 3 2020-05-04 Children and teenagers with refractory/relapsing solid tumor
• Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents with Sickle Cell Disease during Vaso-Occlusive Crisis Ended
  2024-513440-29-00 10 2025-06-25 Sickle cell disease vaso-occlusive crisis
• A Study of REGN7544 for the Treatment in Adult Patients with Sepsis-Induced Hypotension. Ended
  2024-514946-35-00 4 2025-06-24 Sepsis-Induced Hypotension
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in … Ended
  2024-511057-22-00 5 2024-12-04 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• Prospective and multicentre evaluation of 3 different doses of IV busulfan associated with fludarabine and thymoglobuline in the conditionin … Ended
  2024-516435-27-00 4 2024-11-05 High-risk myeloïd malignancies
• Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection Ended
  2023-509684-24-00 7 2024-10-31 Hepatitis B
• SCLERITA - Safety and efficacy of itacitinib in adults with systemic sclerosis: a phase II, randomized, controlled trial Ended
  2024-513648-27-00 4 2024-10-25 Patients with newly or active diffuse Systemic sclerosis (SSc) at the
• Safety and Efficacy of NMD670 in Adult Patients with Type 1 and Type 2 Charcot-Marie-Tooth Disease Ended
  2023-507892-23-00 4 2024-08-30 Charcot-Marie-Tooth Disease Type 1 and Type 2
• A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Modera … Ended
  2023-505433-27-00 5 2024-08-13 Atopic Dermatitis
• Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis Ended
  2023-508679-34-00 4 2024-07-30 Ulcerative Colitis
• Phase 2b study to investigate the safety and efficacy of TIN816 in SA-AKI Ended
  2023-505903-22-00 4 2024-07-02 Sepsis associated acute kidney injury
• Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction Ended
  2023-506210-40-00 5 2024-06-28 Heart Failure due to Systemic Left Ventricular Systolic Dysfunction
• Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar ) Ended
  2023-506229-12-00 4 2024-06-26 Osteosarcoma in Children
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab in participants aged 12 years and older with moderate-to-severe atop … Ended
  2023-506558-20-00 5 2024-06-26 Dermatitis atopic
• A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy. Ended
  2023-504892-25-00 5 2024-06-14 Narcolepsy
• Clinical trial of V940 and pembrolizumab in people with resectable locally advanced cutaneous squamous cell carcinoma Ended
  2023-505712-37-00 10 2024-06-06 The participants must have a histologically confirmed diagnosis of res
• A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherap … Ended
  2022-502653-34-01 11 2024-05-30 Atopic dermatitis and moderate-to severe atopic hand eczema
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended
  2022-501196-41-00 5 2024-05-29 Dermatitis atopic

Showing 649–672 of 800 trials